#SocPharm Tweetchat Transcript 11/17/2010

xpetit:
Welcome to the marketing & social media pharma chat (#socpharm). I am your host tonight Xavier Petit #socpharm

EileenOBrien:
Hi Xavier, so nice to be a guest tonight & have you in the driver’s seat! #socpharm

xpetit:
the basics: We?ll assume that all tweets within #socpharm are your own and not your employers (unless otherwise specified) #socpharm

xpetit:
thanks for having me! #socpharm

xpetit:
My tweets are certainly my own #socpharm

kikilitalien:
. @xpetit looking forward to the #socpharm chat!

xpetit:
a little abt me I work in pharma (shire) & I have a great interest in emerging media (are they really emerging) including SM #socpharm

xpetit:
Specifically very interested on how can pharma enter the SM space and what value we can provide #socpharm

xpetit:
We?ll get to this topic but first thing first.T1 one is related to regulatory are you ready? #socpharm

PR_in_Pink:
Hi there– looking forward to tonight’s discussion #socpharm

EileenOBrien:
Ready! #socpharm

xpetit:
Was @ a conference today and again. An agency stated that pharma is afraid of sm because of Adverse Event? #socpharm

xpetit:
so there it is: Is pharma afraid of SM because of AE reporting and specificially because pharma does no want to report them? #socpharm

xpetit:
I have my opinion on that but before I start, any thoughts out there? #socpharm

EileenOBrien:
@xpetit Gr8 question. I know I’ve heard @swoodruff state that AEs are the big red herring. Easy for pharma to blame to avoid sm. #socpharm

NatBourre:
RT @xpetit: so there it is: Is pharma afraid of SM because of AE reporting and specificially because pharma does no want to report them? #socpharm

EileenOBrien:
Certainly SM should tie back into AE reporting mechanisms that exist, but it’s an easy excuse. Others? #socpharm

PR_in_Pink:
Our clients had concerns about monitoring SM chats, forums, etc b/c of AEs. So yes, @xpetit from my experience there is fear. #socpharm

PR_in_Pink:
However unfounded….#socpharm

xpetit:
agreed.. it has to be a consideration and be addressed. #socpharm

xpetit:
thanks pr_in_pinks… I am sure that it is indeed a concern but is it the main reason? #socpharm

EileenOBrien:
Heard from @melissakdavies that she’s working on update to seminal AE research in SM #socpharm

stevemassi:
Interesting, as the information on AEs points to a very small # reported on SM to date #socpharm

xpetit:
absolutely @stevemassi #socpharm

PR_in_Pink:
@xpetit SM is still the elephant in the room for pharma and an excuse, but not the main reason. #socpharm

A0K:
@xpetit yes. AER is just too much to ask of pharma. Especially when it endangers them. They’re incentivized against it. #socpharm

xpetit:
agree on that to @pr_in_pink #socpharm

EileenOBrien:
@a0k Which is such a shame… #socpharm

NatBourre:
Can’t wait to see new data RT @EileenOBrien Heard from @melissakdavies that she’s working on update to seminal AE research in SM #socpharm

xpetit:
@Aok. Not sure that’s the real issue here. if you want to report you can regardless of SM no? #socpharm

stevemassi:
Is the other issue lack of tactical ROI, where #sm may encourage ROR (return on relationship)? #socpharm

NatBourre:
@xpetit Canada MSWatch.ca recently shut down because they had drug mentions including some AE’s. Decided not to monitor / edit #socpharm

xpetit:
My opinion is that pharma is not afraid of AE. Pharma is afraid of DDMAC and regulators rightfully so #socpharm

xpetit:
With no clarity of liability, responsibility isn’t engaging on one platform creating a precedent? Let me clarify #socpharm

PR_in_Pink:
That’s it! RT @xpetit: My opinion is that pharma is not afraid of AE. Pharma is afraid of DDMAC and regulators rightfully so #socpharm

xpetit:
leads me to T2: Does engaging on a sm platform create a precedent and therefore requires to then monitor this platform forever? #socpharm

xpetit:
Ex: if as a pharma co I correct an entry on Wikipedia? Am I liable to correct all content regarding my products? Forever? #socpharm

EileenOBrien:
@xpetit I think if you own the platform then you should monitor it for as long as you own it. In terms of Wikipedia, no. #socpharm

xpetit:
@stevemassi: very interesting comments… I think your onto something..we’ll adress this in T3 #socpharm

xpetit:
agreed on ownership and liability… but still not sure about the other. I struggle with that one #socpharm

stevemassi:
T2 If pharma were monitoring the #SM space, wouldn’t they want to correct bad info if they were able? But not be held liable #socpharm

PR_in_Pink:
T2: SM is an investment of time. If you start it, you should grow it and maintain it. Pharma isn’t an exception. #socpharm

xpetit:
PR_in_Pink yes that’s it. let’s call is a night! aha (i know that was simplistic) #socpharm

stevemassi:
T2 on platforms they do not own as @eileenobrien stated #socpharm

EileenOBrien:
Wikipedia is a interesting case. All you can do is try to correct bad info & present useful/neutral info. #socpharm

xpetit:
There’s a difference of long terms for relationship (user experience) and regulatory liability though #socpharm

xpetit:
what is the status of limitation for SM? no guidelines… #socpharm

bwrose6846:
Some pharma seems afraid of commitment, too. #socpharm

stevemassi:
Is the liability question really how many times does pharma have to monitor and address/fix the same issue on the same platform? #socpharm

xpetit:
@bwrose6846 that a great point. Some are afraid. some are not even aware of it… #socpharm